Ticker Symbol: MNKD
Mannkind Corp
$4.88 - 20-11-2024 4 p.m. ET
Exchange: NASDAQ
Country:
United States
Currency:
USD
Asset
Type: Common Stock
CIK:0000899460
Company Profile
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 30930 Russell Ranch Rd Ste 300
Website: www.mannkindcorp.com
CEO: Michael Castagna
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $3.87
Change:
-$0.16
(
-3.97%)
Days Range: $3.86 - $4.13
Beta: 1.22
52wk. High: $5.75
52wk. Low: $3.17
Ytd. Change -27.50%
50 Day Moving Average: $4.19
200 Day Moving Average: $4.30
Shares Outstanding: 268355182
Valuation
Market Cap: 103.9B
PE Ratio: -21.46
EPS (TTM): -0.1803
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A